

Resource Summary Report

Generated by [RRID](#) on Aug 18, 2026

pcDNA3.3_SARS2_omicron BA.2

RRID:Addgene_183700

Type: Plasmid

Proper Citation

RRID:Addgene_183700

Plasmid Information

URL: <http://www.addgene.org/183700>

Proper Citation: RRID:Addgene_183700

Insert Name: Spike (BA.2)

Organism: SARS-CoV-2

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:35857439](#)

Vector Backbone Description: Backbone Size:5500; Vector Backbone:pcDNA3.3; Vector Types:Mammalian Expression, Lentiviral, Retroviral; Bacterial Resistance:Ampicillin

Plasmid Name: pcDNA3.3_SARS2_omicron BA.2

Relevant Mutation: c-terminal 18 aa deletion

Record Creation Time: 20220422T222039+0000

Record Last Update: 20260815T081134+0000

Ratings and Alerts

No rating or validation information has been found for pcDNA3.3_SARS2_omicron BA.2.

No alerts have been found for pcDNA3.3_SARS2_omicron BA.2.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Choi S, et al. (2026) Fc-mediated antibody functions are associated with disease severity in COVID-19. *Frontiers in immunology*, 17, 1797975.

Jung I, et al. (2025) Rapid Discovery of Potent Neutralizing Antibodies against SARS-CoV-2 through Directed Evolution of SARS-CoV-1 Antibodies. *Molecular pharmaceutics*, 22(9), 5316.

Lin MW, et al. (2025) Using Nano-Luciferase Binary (NanoBiT) Technology to Assess the Interaction Between Viral Spike Protein and Angiotensin-Converting Enzyme II by Aptamers. *Biotech (Basel (Switzerland))*, 14(1).

Lin CH, et al. (2024) Inhibitory Efficacy of Main Components of *Scutellaria baicalensis* on the Interaction between Spike Protein of SARS-CoV-2 and Human Angiotensin-Converting Enzyme II. *International journal of molecular sciences*, 25(5).

Ho CL, et al. (2024) Long-term analysis of humoral responses and spike-specific T cell memory to Omicron variants after different COVID-19 vaccine regimens. *Frontiers in immunology*, 15, 1340645.

Connor RI, et al. (2024) Characteristics and Functions of Infection-enhancing Antibodies to the N-terminal Domain of SARS-CoV-2. *Pathogens & immunity*, 9(2), 1.

Eden T, et al. (2024) Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire. *Nature communications*, 15(1), 4728.

Dacon C, et al. (2023) Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. *Cell host & microbe*, 31(1), 97.

Bains A, et al. (2023) The Effect of Select SARS-CoV-2 N-Linked Glycan and Variant of Concern Spike Protein Mutations on C-Type Lectin-Receptor-Mediated Infection. *Viruses*, 15(9).

Ha DP, et al. (2023) GRP78 Inhibitor YUM70 Suppresses SARS-CoV-2 Viral Entry, Spike Protein Production and Ameliorates Lung Damage. *Viruses*, 15(5).

Connor RI, et al. (2023) Characteristics and functions of infection-enhancing antibodies to the N-terminal domain of SARS-CoV-2. *bioRxiv : the preprint server for biology*.

Zhang L, et al. (2022) An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2. *EMBO molecular medicine*, 14(11), e16109.